Genprex is on the Cutting Edge of Lung Cancer Treatment Development
February 3, 2021
By Michael Redman, Genprex’ Chief Operating Officer
Mr. Redman provides his reaction to a recent article in ONCOLOGY® and discusses how Genprex is harnessing breakthroughs in lung cancer treatment:
A recent article in ONCOLOGY® interviewed Rogerio C. Lilenbaum, MD, director of Banner MD Anderson Cancer Center, to discuss current and future trends in lung cancer treatment. In the article, “Harnessing the Breakthroughs in Lung Cancer Treatment,” Dr. Lilenbaum discusses how targeted therapies and immunotherapies are being utilized to treat lung cancer patients based on genetic mutations.
Dr. Lilenbaum on targeted therapies:
“We now have the data for osimertinib [Tagrisso®] in the adjuvant setting for EGFR-positive patients. That, to me, is a breakthrough, and it will change the way we do adjuvant treatment,” said Lilenbaum.
Dr. Lilenbaum on immunotherapies:
“More importantly, we will see data for immunotherapy in the early-stage settings. So I think, again, that how you apply the knowledge that we’ve acquired in late-stage disease to early-stage disease is among the most potentially impactful areas of research. When you [use immunotherapy] in early-stage disease, what you’re doing is not only prolonging life, but increasing the cure rate. And that’s what we want to see,” said Lilenbaum.
Genprex is harnessing the power of these breakthroughs in lung cancer treatment, using cutting-edge technology and research to bring potentially life-changing therapies to lung cancer patients. Our lead drug candidate, REQORSA™ immunogene therapy, is initially targeting non-small cell lung cancer (NSCLC). REQORSA utilizes our unique, proprietary, nonviral ONCOPREX® Nanoparticle Delivery System, in combination with approved targeted therapies and immunotherapies, such as Tagrisso and Keytruda®.
“Although therapies like Tagrisso and Keytruda have changed the landscape of late-stage NSCLC, many patients do not respond to these therapies and often the benefits are short-lived,” said Michael Redman, Chief Operating Officer at Genprex. “Furthermore, there is no standard of therapy for second line treatment and REQORSA could address this shortfall.”
The Company’s Acclaim-1 and Acclaim-2 clinical trials, which combine REQORSA with Tagrisso and Keytruda, respectively, are on track to be initiated in the first-half of 2021. To learn more about Genprex and its lead drug candidate, REQORSA, please visit genprex.com.